# DCCC ctDNA Researchcenter Annual Meeting

Time: 22 November 2021 at 9.00 -23 November 2021 at 15.00/16.30 Place: Comwell H.C.Andersen Odense, Claus Bergs Gade 7, 5000 Odense

## Day 1

- 09.00 Arrival. Coffee and bread
- 10.10 Welcome and status from center management

#### Morning session: Clinical application

Chairman: Lars Dyrskjøt

- 10.25 Circulating tumor DNA for early detection of recurrence and risk-stratification in melanoma Magnus Petur Bjarnason Obinah
- 10.45 Evaluation of TriMeth for early detection of colorectal cancer in asymptomatic individuals Sarah Østrup Jensen
- 11.05 Early detection of treatment failure by circulating tumor DNA in advanced non-small cell lung cancer
- Malene Frank
- 11.25 Tumor-agnostic circulating tumor DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: a prospective cohort study *Claus Lindbjerg Andersen*
- 11:45 KEY NOTE: Title TBA (virtual talk) Prof. Thomas Powles, BARTS HEALTH NHS TRUST
- 12:30 Lunch

#### Noon Session: ctDNA detection methods

Chairman: Morten Mau-Sørensen

- 13.15 Sensitive detection of ctDNA using whole genome sequencing Amanda Frydendahl Boll Johansen and Iver Nordentoft
- 13.30 Error characterization and statistical modelling improves circulating tumor DNA detection by droplet digital PCR

Tenna Henriksen

13.45 ctMETHfinder, a tool for identification of ctDNA methylation markers from solid tissue methylation datasets.

Jesper Bramsen

- 14.00 Ultra-deep plasma sequencing of colorectal cancer patients Mads Heilskov Rasmussen
- 14.15 A UMI based deep targeted sequencing approach for tumor-guided ctDNA detection in plasma and urine samples from patients with bladder cancer *Emil Christensen*
- 14:30 Coffee/cake

## Afternoon session: ctDNA focused projects

Chairman Claus Lindbjerg Andersen

14:50 KEY NOTE: Monitoring of Minimal Residual Disease using ctDNA: A lung TRACERx experience. Dr. Chris Abbosh, Principal Clinical Fellow - AstraZeneca clinical fellowship, UCL

## 15:35 Poster flash talks

- 1. Novel DNA methylation markers for sensitive detection of ctDNA in plasma from patients with upper gastrointestinal cancers, *Cecilie Riis Iden*
- 2. Results from the OPTIPAL II study, Louise Callesen
- 3. Low-pass WGS and deep targeted sequencing of plasma derived cfDNA for outcome prediction in mCRPC patients treated with Enzalutamide or Abiraterone in first-line, *Maibritt Nørgaard*

- 4. Implementation of cfMeDIP-seq for investigation of methylated ctDNA in metastatic castration resistant prostate cancer, *Karoline Torstensen*
- 5. SFRP1 Promoter Hypermethylation in Plasma as a Prognostic Marker for Survival in Patients with Stage IV Pancreatic Adenocarcinoma, *Benjamin Stubbe*
- 16:20-18:00 Poster session and an opportunity to discuss projects (posterboards are 2.5mx1m (hxw)) beer/wine/soda

18:30-21:00 Dinner

## Day 2

08:10 Welcome back

#### Morning session: Activities, plans, and support from the National Infrastructures

Chairman Karen Lise Garm Spindler

08:15	Best practice for liquid biopsy collection and pre-analytical processing (NI1) <i>Rikke Fredslund Andersen and Estrid Høgdall</i>
09:00	Methods for ctDNA detection (NI2)
	Niels Pallisgaard and Mads Heilskov Rasmussen
09:45	Break
10.30	Bioinformatic procedures and algorithms for analysis and calling of ctDNA (NI3) Lasse Maretty and Filipe Garrett Vieira
11:00	Health Economy in ctDNA projects (NI4)
	Liza Sopina
11:45	Lunch

#### Noon session: ctDNA based intervention studies

## Chairman Niels Pallisgaard

Onainnainn	
12.45	IMPROVE-IT2 - implementing noninvasive circulating tumor DNA analysis to optimize the operative and postoperative treatment for patients with colorectal cancer – intervention trial 2 Kåre Gotschalck
13.05	TOMBOLA - Treatment Of Metastatic Bladder cancer at the time Of biochemical reLApse following radical cystectomy <i>Karin Birkenkamp-Demtröder</i>
13.25	NOAC-9 - Phase III Randomized Nordic Anal Cancer Group Study on Circulating Tumor DNA guided Follow-Up <i>Karen-Lise Garm Spindler</i>
13.45	CIRCPAC – status on a national study for implementation of ctDNA in patients with lokalized pancreas cancer Sidsel Christy Lindgaard
14:00	Closing remarks
14:30	Coffee/Cake
1-1.00	Concer Oake

15:00 - 16:30 Meeting in the steering committee